82 results on '"Bhatia M."'
Search Results
2. Influence of Mg/B ratio and SiC doping on microstructure and high field transport Jc in MgB 2 strands
3. Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS)
4. Peripheral silent periods in essential tremor
5. Reduced susceptibility of carbapenem-resistant Klebsiella pneumoniae to biocides: An emerging threat
6. An evaluation of dark field microscopy, culture and commercial serological kits in the diagnosis of leptospirosis
7. The Utility of P-Wave Terminal Force V1 is Limited by its Reliability
8. Alkaptonuria.
9. Lunate dislocation causing median nerve entrapment.
10. Atypical Kleine--Levin syndrome: can insomnia and anorexia be features too?
11. Septo-optic dysplasia: Magnetic Resonance Imaging findings.
12. O0019 Periodic limb movement in chronic renal failure: an actigraph evaluation
13. An epidemic of avoidable caesarean deliveries in the private sector in India: Is physician-induced demand at play?
14. Dandy-Walker variant: Prenatal diagnosis by ultrasonography.
15. Sinonasal mucormycosis: Diagnosis using computed tomography.
16. Gastroschisis—antenatal diagnosis.
17. Lissencephaly with agenesis of corpus callosum: A rare anomaly.
18. Pharmacokinetics (PK) Of IV And Po Mycophenolate Mofetil (MMF) In Age Adjusted Pediatric And Adolescent Allogeneic Stem Cell Transplant (AlloSCT) Recipients: Significantly Higher CLss AND Vss IN PATIENTS <6 YEARS OF AGE
19. A Pilot Study of Reduced Intensity Conditioning (RI) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism in Patients With Symptomatic Sickle Cell Disease (SCD)
20. Preliminary Results of Non-Ablative Conditioning (NAC) with Busulfan (Bu), Fludarabine (Flu) and Alemtuzumab followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease (SCD)
21. Radiological quiz.
22. Radiological quiz.
23. Giant recurrent lipoma of trunk weighing eight kilograms.
24. Long Term Organ Stability and Outcome in Children and Adolescents With Sickle Cell Disease (SCD) Following Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation (SCT)
25. Pharmacokinetics Of Mycophenolate Mofetil (MMF) In Combination With Tacrolimus In Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients≤12 Years Of Age
26. Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults
27. Pericardial Effusion (PEF) is a Major Independent Risk Factor Associated with a Significant Decrease in Survival in Pediatric Stem Cell Transplantation (SCT) Recipients
28. Low Molecular Weight Heparin (LMWH) Prophylaxis (PPX) in Pediatric Recipients following Pediatric Myeloablative Stem Cell Transplant (SCT) at High Risk for Sinusoidal Obstructive Syndrome (SOS): Is it Safe and Does it Make a Difference?
29. Preliminary Results of a Phase I Study of Immuno-Chemotherapy (CTX) Conditioning with Gemtuzumab Ozogamicin (GO), Busulfan (Bu) and Cyclophosphamide (Cy) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) in Pediatric Recipients with High Risk (HR) CD33+ Acute Myelogenous Leukemia (AML)
30. Survivorship of the bio-action metatarsophalangeal joint arthroplasty for hallux rigidus: 5-year follow-up
31. Journal scan: American Journal of Roentgenology.
32. Microbiology and Antimicrobial Resistance of Clinical Isolates Early Post Left Ventricular Device Implantation.
33. 185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma: A single institution pilot study
34. First metatarsophalangeal joint arthrodesis – Do joint configuration and preparation technique matter?
35. Reduced Toxicity Conditioning (RTC) and Allogeneic Stem Cell Transplantation (AlloSCT) for Pediatric Sickle Cell Disease (SCD): Significant Improvement in Physical Functioning
36. Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population
37. Synergism between hydrogen sulfide (H2S) and nitric oxide (NO) in vasorelaxation induced by stonustoxin (SNTX), a lethal and hypotensive protein factor isolated from stonefish Synanceja horrida venom
38. Usefulness of antimyosin antibody imaging for the detection of active rheumatic myocarditis.
39. Structure/function relationship of the dopamine D2 receptors
40. Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (AlloSCT) In Children and Adolescent Recipients is Associated With Very Low Regimen Related and Non-Relapse Mortality (NRM): However, Chemonaive Patients Following Umbilical Cord Blood Transplant (UCBT) have a Higher Incidence of Primary Graft Failure (PGF)
41. 315: Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients
42. 76: Reduced intenity allogeneic stem cell transplantion followed by targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33+ acute myeloid leukemia
43. A pilot study of myeloablative (MA) autologous stem cell (autoSCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children and adolescents with relapsed hodgkin’s disease (HD) and non-hodgkin’s lymphoma (NHL)
44. Higher clearance rates of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (allosct) recipients
45. Safety of Probiotic Usage in Children Undergoing Hematopoietic Cell Transplantation (HCT): A Preliminary Report
46. Familial Haploidentical (FHI) T-Cell Depleted (TCD) Transplantation in High-Risk Sickle Cell Disease (IND 14359)
47. Iv Busulfan Administered Q12 Vs Q6 Hrs During Conditioning of Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Has Comparable Pharmacokinetics and Significant Reduction in Nursing/Pharmacist Costs
48. Reduced Toxicity Conditioning (RTC) and Allogeneic Stem Cell Transplantation (alloSCT) in 100 Consecutive Pediatric Recipients: Very Low Incidence of Day 100 Transplant Related Mortality (TRM)
49. A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)
50. CD34+ Stem Cell Selection and CD3+ Addback for Pediatric Recipients of Matched Unrelated Adult Donor (MUD) Peripheral Blood Stem Cell Transplantation (PBSCT) Preliminary Results of Day 100 Trm, Immune Reconstitution (IR), PTLD, Systemic Viral Infections (SVI), and Invasive Fungal Infections (IFI)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.